AN2 Therapeutics, Inc.

Historical 13F Holders

Symbol
ANTX
CUSIP
037326105
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 037326105 since 12/18/2024, largest first.

Filer % of Class Filed
Coastlands Capital LP 13G/A
10.0% 11/13/2026
Event 9/30/2026
Commodore Capital LP 13G/A
9.9% 11/16/2026
Event 9/30/2026
Coastlands Capital Partners LP 13G
9.3% 6/4/2025
Event 5/28/2025
Vivo Opportunity Fund Holdings, L.P. 13G
8.0% 3/13/2026
Event 3/10/2026
Adjuvant Global Health Technology Fund, L.P. 13G/A
7.9% 2/28/2025
Event 12/31/2024
Integrated Core Strategies (US) LLC 13G
6.3% 3/13/2026
Event 3/6/2026
Eric Easom 13G/A 6.2% 11/13/2026
Event 9/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (6)
Almitas Capital LLC 13G/A 4.1% 5/15/2026
Event 3/31/2026
Brii Biosciences Ltd 13G/A 3.1% 2/14/2025
Event 12/31/2024
BML Investment Partners, L.P. 13D/A 1.4% 6/18/2025
Event 6/17/2025
Frazier Life Sciences Public Fund, L.P. 13G/A
0% 2/14/2025
Event 12/31/2024
RA Capital Management, L.P. 13G/A
0% 2/14/2025
Event 12/31/2024
TCG Crossover GP I, LLC 13G/A
0% 2/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 88 26.9 M $143M
2026 Q2 66 24.6 M $119M
2026 Q1 52 21.9 M $74.8M
2025 Q4 38 8.67 M $9.88M
2025 Q3 36 8.28 M $10.5M
2025 Q2 38 8.29 M $8.78M
2025 Q1 39 14.3 M $19.5M
2024 Q4 39 14.5 M $20.1M
2024 Q3 32 13.5 M $14.5M
2024 Q2 46 19.4 M $41.7M
2024 Q1 55 18.7 M $60.9M
2023 Q4 52 20.4 M $418M
2023 Q3 38 19.9 M $320M
2023 Q2 32 11.7 M $99.9M
2023 Q1 39 9.60 M $94.8M
2022 Q4 37 9.76 M $92.9M
2022 Q3 39 9.50 M $165M
2022 Q2 37 9.39 M $72.4M
2022 Q1 19 8.95 M $134M